Effects of panobinostat (LBH589) and everolimus (RAD001) combination on the proliferation and the viability of HL cell lines. (A) Cells were treated with 0.02 to 0.1μM of LBH589 or 0.1μM of RAD001 or in combination for 48 hours, and cell viability was determined by an MTS assay. Each value represents the mean ± SEM of the results of 3 independent experiments performed in triplicate. **P < .005. (B) HL cell lines were treated or not with 0.02μM of LBH589 and/or RAD001 for 48 hours. Apoptosis was determined by annexin V–FITC/propidium iodide double staining. Percentages of cells showing apoptosis (combined right quadrants) are shown in the boxes. (C) Summary of the results of annexin V–FITC/propidium iodide double staining from 3 independent experiments. Each value represents the mean of 3 independent experiments performed in triplicate. **P < .005. (D) Cells were incubated with LBH589 (0.02μM) and/or RAD001 (0.1μM) for 48 hours, and the cell cycle was analyzed by flow cytometry using propidium iodide staining. The combination of panobinostat with everolimus significantly increased the percentage of cells in the G₂/M phase. Each value is the mean of 3 independent experiments. (E) Summary of the percentage of cells in G₂/M phase. **P < .005.